Clearmind Medicine Inc. Research and Development Expense
Clearmind Medicine Inc. (CMND) reported Research and Development Expense of $640.49 thousand for the 3-month period ending 2026-01-31, per its 6-K filed 2026-03-12.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2026-03-12
- Clearmind Medicine Inc. research and development expense for the quarter ending 2023-01-31 was 792.46K CAD, a 86.79% increase year-over-year.
- Clearmind Medicine Inc. research and development expense for the quarter ending 2022-01-31 was 424.26K CAD.
CAD
| Period end | Research And Development Expense 3 month | Research And Development Expense 12 month |
|---|---|---|
| 2023-01-31 | 792.46K CAD 6-K · filed 2023-03-17 | |
| 2022-10-31 | 4.21M CAD 20-F · filed 2023-02-06 | |
| 2022-01-31 | 424.26K CAD 6-K · filed 2023-03-17 | |
| 2021-10-31 | 646.49K CAD 20-F · filed 2023-02-06 |
USD
| Period end | Research And Development Expense 3 month | Research And Development Expense 3 month as first filed | Research And Development Expense 6 month | Research And Development Expense 9 month | Research And Development Expense 12 month |
|---|---|---|---|---|---|
| 2026-01-31 | $640.49K 6-K · filed 2026-03-12 | $1.06M derived: sum of 2 quarters · filed 2026-03-12 | $1.78M derived: sum of 3 quarters · filed 2026-03-12 | $2.24M derived: sum of 4 quarters · filed 2026-03-12 | |
| 2025-10-31 | $420.18K derived: 20-F 12 month − 6-K 9 month · filed 2026-01-20 | $1.14M derived: sum of 2 quarters · filed 2026-01-20 | $1.60M derived: sum of 3 quarters · filed 2026-01-20 | $2.06M 20-F · filed 2026-01-20 | |
| 2025-07-31 | $723.05K 6-K · filed 2025-09-11 | $1.17M derived: sum of 2 quarters · filed 2025-09-11 | $1.64M 6-K · filed 2025-09-11 | $2.12M derived: sum of 4 quarters · filed 2026-03-12 | |
| 2025-04-30 | $451.86K 6-K · filed 2025-06-12 | $913.29K 6-K · filed 2025-06-12 | $1.40M derived: sum of 3 quarters · filed 2026-03-12 | $1.75M derived: sum of 4 quarters · filed 2026-03-12 | |
| 2025-01-31 | $461.44K 6-K · filed 2026-03-12 | $947.93K derived: sum of 2 quarters · filed 2026-03-12 | $1.29M derived: sum of 3 quarters · filed 2026-03-12 | $1.62M derived: sum of 4 quarters · filed 2026-03-12 | |
| 2024-10-31 | $486.49K derived: 20-F 12 month − 6-K 9 month · filed 2026-01-20 | $832.37K derived: sum of 2 quarters · filed 2026-01-20 | $1.16M derived: sum of 3 quarters · filed 2026-01-20 | $1.38M 20-F · filed 2026-01-20 | |
| 2024-07-31 | $345.88K 6-K · filed 2025-09-11 | $668.84K derived: sum of 2 quarters · filed 2025-09-11 | $896.32K 6-K · filed 2025-09-11 | $1.06M derived: sum of 4 quarters · filed 2026-03-12 | |
| 2024-04-30 | $322.96K 6-K · filed 2025-06-12 | $550.43K 6-K · filed 2025-06-12 | $710.77K derived: sum of 3 quarters · filed 2026-03-12 | $974.73K derived: sum of 4 quarters · filed 2026-03-12 | |
| 2024-01-31 | $12.75K 6-K · filed 2026-03-12 | $227.48K 6-K · filed 2024-03-19 | $387.82K derived: sum of 2 quarters · filed 2026-03-12 | $651.77K derived: sum of 3 quarters · filed 2026-03-12 | $969.35K derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-10-31 | $375.07K derived: 20-F 12 month − 6-K 9 month · filed 2026-01-20 | $639.03K derived: sum of 2 quarters · filed 2026-01-20 | $956.60K derived: sum of 3 quarters · filed 2026-01-20 | $1.54M 20-F · filed 2026-01-20 | |
| 2023-07-31 | $263.95K 6-K · filed 2024-09-16 | $581.53K derived: sum of 2 quarters · filed 2024-09-16 | $1.17M 6-K · filed 2024-09-16 | ||
| 2023-04-30 | $317.57K 6-K · filed 2024-06-13 | $905.20K 6-K · filed 2024-06-13 | |||
| 2023-01-31 | $587.63K 6-K · filed 2024-03-19 | ||||
| 2022-10-31 | $3.08M 20-F · filed 2025-01-22 | ||||
| 2022-04-30 | $1.16M 6-K · filed 2023-06-14 | $1.47M 6-K · filed 2023-06-14 | |||
| 2021-10-31 | $473.65K 20-F/A · filed 2024-03-18 |